HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
Company in full compliance for continued listing
MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ('HCWB' or the 'Company') (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC ('Nasdaq') informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the 'Equity Rule').
On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied the requirements of the Equity Rule. On May 13, 2025, the Company received formal notice from Nasdaq that it regained compliance with the bid price requirement in Listing Rule 5550(a)(2), the public float requirement in Listing Rule 5550(a)(4), and the market value of publicly held shares requirement in Listing Rule 5550(a)(5). Therefore, the Company now meets all Nasdaq Capital Market listing requirements for continued listing, and these matters are closed.
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company's immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients' quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company's lead product candidate, HCW9302, was developed using the Company's legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-006, HCW11-018 and HCW11-027. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Company Contact:
Rebecca ByamCFOHCW Biologics Inc.rebeccabyam@hcwbiologics.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Wolfe Research Upgrades Charter Communications (CHTR) on Potential Tax Benefit
Charter Communications, Inc. (NASDAQ:CHTR) is one of the 11 best performing Warren Buffett stocks in 2025. On June 20, Wolfe Research raised the company's stock from an 'Underperform' rating to a 'Peer Perform' rating. According to the analysts, the key reason for the upgrade is the potential financial benefits for Charter from the anticipated reinstatement of 100% bonus depreciation. A broadband satellite hovering in the sky, highlighting the company's satellite-based broadband communication solutions. In 2017, the Tax Cuts and Jobs Act introduced 100% bonus depreciation. This move allowed companies to deduct the full cost of certain capital expenditures immediately. But this provision began phasing out in 2023. In 2025, the House passed the 'One Big Beautiful Bill', aiming to reinstate full bonus depreciation through 2029 (2030 for some assets). The bill seeks to stimulate capital investment and reduce near-term tax burdens for infrastructure-heavy firms like Charter. Charter stands out as a prime beneficiary with its $93.6 billion debt load and capital-intensive broadband infrastructure. Wolfe Research's analysts highlighted that the company could see $1.8 billion in tax savings in 2025 alone. This is a 30% free cash flow (FCF) boost, potentially doubling FCF per share by 2027. Charter Communications, Inc. (NASDAQ:CHTR) is a broadband connectivity and cable operator company. It provides internet, video, voice, and mobile services to over 32 million customers across 41 US states. Its leading brand is Spectrum, which offers high-speed internet, cable TV, home phone, and mobile services to both residential and business clients. While we acknowledge the potential of CHTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
China's $1 Trillion Power Player Is Quietly Backing Out of Wall Street
China Investment Corporationthe $1.3 trillion heavyweight once courted by every major Wall Street firmis stepping back from the U.S. private asset scene. CIC recently pulled the plug on a proposed $1 billion sale of stakes in funds managed by KKR (NYSE:KKR), Carlyle (NASDAQ:CG), and TPG (NASDAQ:TPG), amid concerns it would amplify the optics of its broader U.S. retreat. Insiders say the fund was spooked by the political climate and the potential fallout from being perceived as bailing out of American private equity. While CIC attributes the decision to prudent risk management, the context suggests a deeper recalibration in response to mounting headwinds from both Washington and Beijing. Warning! GuruFocus has detected 4 Warning Signs with CG. This isn't just about one canceled sale. CIConce the savior of Morgan Stanley (NYSE:MS) during the 2008 crisis and an early backer of Blackstonehas been gradually throttling down its U.S. exposure for years. Alternative asset allocations fell below target in 2023. Compliance scrutiny has tightened. And CIC, once central to Wall Street's capital flows, now finds itself sidelined in co-investments and forced into sidecar vehicles to avoid regulatory tangles. New U.S. investment policies under Trump's America First agenda, along with plans to fast-track only friendly foreign investors, are making it harder for Chinese money to find a seat at the table. So where does CIC go next? The fund is doubling down on emerging markets, renewable energy, and dealmaking with Middle Eastern partners. It's still deploying capitalbut with less swagger than before. Internally, capital injections have slowed, talent has trickled out, and its global mandate has been diluted by rising domestic players like Central Huijin. For a fund born to project China's financial influence abroad, CIC is increasingly boxed incaught between politics, regulation, and a shrinking pool of strategic, high-return opportunities. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Redburn-Atlantic Initiates 'Sell' Rating on Domino's Pizza (DPZ) Due to Weak Organic Traffic and Profit Margin Concerns
Domino's Pizza, Inc. (NASDAQ:DPZ) is one of the 11 best performing Warren Buffett stocks in 2025. On June 10, Redburn-Atlantic initiated coverage on the company's stock with a 'Sell' rating. The firm also set its price target for Domino's Pizza's shares at $340.00. Jonathan Weiss/ According to a research note, Redburn-Atlantic said the basis of their price target is a forward P/E multiple of 19.7 times based on the firm's estimated 2025 earnings. The analysts also noted that Domino's Pizza's carryout orders significantly outperform delivery orders. While this trend could support sales volumes, the analysts added, it may also lead to reduced profit margins for the company. Several other issues stick out in the analysts' perspective. First, they point out weak organic traffic. They highlighted that Domino's is experiencing weak organic traffic. Second, Redburn-Atlantic indicated that Domino's business model highly relies on lower-income consumers. As a result, the firm concluded that the growth of system sales for Domino's is under threat. Domino's Pizza, Inc. (NASDAQ:DPZ) is a global restaurant operator and franchisor. It offers pizzas and other food items like wings, sandwiches, pasta, and desserts under the Domino's brand. The company operates through three segments: US Stores, International Franchise, and Supply Chain. It serves customers through nearly 19,000 stores across more than 90 countries. While we acknowledge the potential of DPZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
